|Systematic (IUPAC) name|
|Metabolism||Demethylated to dimethadione|
|Half-life||12–24 hours (trimethadione)
6–13 days (dimethadione)
|Mol. mass||143.141 g/mol|
|(what is this?)|
Fetal trimethadione syndrome
If administered during pregnancy, fetal trimethadione syndrome may result causing facial dysmorphism (short upturned nose, slanted eyebrows), cardiac defects, intrauterine growth restriction (IUGR), and mental retardation. The fetal loss rate while using trimethadione has been reported to be as high as 87%.
Trimethadione, 3,5,5-trimethyloxazolidine-2,4-dione, may be synthesized by methylating 5,5-trimethyloxazolidine-2,4-dione with dimethylsulfate. Starting 5,5-trimethyloxazolidine-2,4-dione is in turn synthesized by the cyclocondensation of the ester of 2-hydroxyisobutyric acid with urea.
Dimethadione is an active metabolite with anticonvulsant properties, used in determination of intracellular pH. 
- J.S.H. Davies, W. Hook, U.S. Patent 2,559,011 (1951).
- M.A. Spielman, U.S. Patent 2,575,692 (1951).
- Spielman, M. A. (1944). Journal of the American Chemical Society 66 (8): 1244–1245. doi:10.1021/ja01236a005.
|This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it.|